NEW YORK & CHICAGO--(BUSINESS WIRE)--Despite the approval earned by one biosimilar via the 351(k) pathway and the relatively large number of companies that intend to enter the market, their impact on sponsor companies remains uncertain, Fitch Ratings says. Patent and naming disputes, as well as pricing, physician and patient acceptance and actual clinical effectiveness and other issues must all be cleared before certainty about the financial impact can be understood. The approval of Zarxio (fil
| < Prev | Next > |
|---|
